<!doctype html>
<html lang="en">
    <head>
        <meta charset="utf-8"/>
        <meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no"/>
        <meta name="format-detection" content="telephone=no"/>
        <meta name="apple-mobile-web-app-capable" content="yes"/>
        <meta name="apple-mobile-web-app-status-bar-style" content="black"/>
        <title>Important Safety Information</title>
        <link rel="stylesheet" href="../shared/shared-dificid-v4/js/ext/avModal/themes/default.css"/>
        <link rel="stylesheet" href="../shared/shared-dificid-v4/css/shared-main.css"/>
                <link rel="stylesheet" href="css/specific.css" id="link" />

<!--         <script type="text/javascript">
            var currentdate = new Date();
            var time = currentdate.getHours() + ":" + currentdate.getMinutes() + ":" + currentdate.getSeconds();
            var link = document.getElementById("link");
            link.setAttribute("href","css/specific.css?"+ time);
        </script> -->
    </head>
    <body data-pix="true" data-SlideName="SSI" data-productAbbreviation="">
      <section id="wrapper">
            <!-- Landscape Header with Tracking -->
        <header class="landscapeHeader">
                <div class="homeIcon" data-slide="0.0_dificid_v4_home.zip">&nbsp;</div>
                <div class="halfMoon" id="halfMoonTOC">&nbsp;</div>      
            </header>
           
        <section id="contentWrapper">
               <div id="content">
                  <div id="landscape">
                     <div id="scrollableContent">
                        <div class="mainContent">
                            <div class="iniHead bold fs19 lh24 darkGreen">Indication</div>
                              <div class="iniTxtOne roman fs17 lh23 darkGray">
                                  DIFICID is a macrolide antibacterial drug indicated in adults (&ge;18 years of age) for treatment of <span class="italic">Clostridium<br/> difficile</span>-associated diarrhea (CDAD).
                              </div>
                              <div class="iniTxtTwo roman fs17 lh23 darkGray">
                                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other<br/>
                                  antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be<br/>
                                  caused by <span class="italic">C. difficile</span>.
                              </div>
                              <div class="isiHead bold fs19 lh24 darkGreen">Important Safety Information</div>
                              <ul class="isiList roman fs17 lh23 darkGray">
                                  <li>
                                     DIFICID is contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient<br/>in DIFICID.
                                  </li>
                                  <li>
                                      DIFICID should only be used for the treatment of <span class="italic">C. difficile</span>-associated diarrhea. DIFICID is not effective for <br/>treatment of other types of infections due to minimal systemic absorption of fidaxomicin.
                                  </li>
                                  <li>
                                      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and<br/>
                                      face have been reported with fidaxomicin. If a severe hypersensitivity reaction occurs, DIFICID should be<br/>
                                      discontinued and appropriate therapy should be instituted.
                                  </li>
                                  <li>
                                      Only use DIFICID for infection proven or strongly suspected to be caused by <span class="italic">C. difficile.</span> Prescribing DIFICID in<br/>
                                      the absence of a proven or strongly suspected <span class="italic">C. difficile</span> infection is unlikely to provide benefit to the patient<br/>
                                      and increases the risk of development of drug-resistant bacteria.
                                  </li>
                                  <li>
                                      The most common adverse reactions reported in clinical trials are nausea (11%), vomiting (7%), abdominal<br/>
                                      pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%).
                                  </li>
                                  <li>
                                      Among patients receiving DIFICID, 33 (5.9%) withdrew from trials as a result of adverse reactions. Vomiting<br/>
                                      was the primary adverse reaction leading to discontinuation of dosing (incidence of 0.5% for both DIFICID<br/>
                                      and vancomycin patients).
                                  </li>
                                  <li>
                                      The safety and effectiveness of DIFICID in patients &lt;18 years of age have not been established.
                                  </li>
                                  <li>
                                      The recommended dose of DIFICID is one 200 mg tablet orally twice daily for 10 days, with or without food.
                                  </li>
                                  <li>
                                      No dose adjustment is recommended for patients &ge;65 years of age.
                                  </li>
                                  <li>
                                      No dose adjustment is recommended for patients with renal impairment.
                                  </li>
                                  <li>
                                      No dosage adjustments are recommended when co-administering fidaxomicin with substrates of P-gp or<br/>
                                      CYP enzymes.
                                  </li>
                                  <li>
                                      The impact of hepatic impairment on the pharmacokinetics of fidaxomicin has not been evaluated;<br/>
                                      however, because fidaxomicin and its active metabolite (OP-1118) do not appear to undergo significant<br/>
                                      hepatic metabolism, elimination of fidaxomicin and OP-1118 is not expected to be significantly affected by<br/>
                                      hepatic impairment.
                                  </li>
                              </ul>

                              <div class="piBottomLine bold darkGreen">

                                 Before prescribing DIFICID<sup class="piBottomLineSup fs10">&reg;</sup> (fidaxomicin), please read the Prescribing Information.
                              </div>

                              <div class="merckLogo">&nbsp;</div>

                              <div class="copyRight normal gray fs15 lh19"> 
                                 Copyright &copy; 2019 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="bold">Merck &amp; Co., Inc.</span> All rights reserved.<span class="copyRightr">US-DIF-00272 07/19</span>
                              </div>
                              <div class="btnspace">&nbsp;</div>
                        </div>
                     </div> <!-- scrollable content end div -->
                  </div> <!-- landscape end div -->            
               </div>
            </section>

        <footer data-count="six">&nbsp;</footer>
      </section><!--//wrapper-->

      <!-- ================= Global popups Start=====================-->
        <section id="globalComponent">&nbsp;</section>
      <!-- ================= Global popups End=====================-->
       
        <script src="../shared/shared-dificid-v4/js/jquery-2.2.3.min.js" charset="utf-8"></script>
        <script src="../shared/shared-dificid-v4/shared-main.js" charset="utf-8"></script>
    </body>
</html>